Investees
Investees
We are delighted to share our confirmed investees. The company profiles are listed in alphabetical order from A-Z. Click on the company logo to jump to the information.
Cyban
Cyban is advancing the way brain injuries are detected and managed.
Our mission is to change the standard of care in how brain injuries are detected and managed by providing cutting edge solutions to enhance clinical decision making.
Our Brain Pulse Monitor provides non-invasive, continuous measures of intracranial pressure, oxygen saturation and cerebral perfusion that are accurate relative to the existing “gold standard” invasive probes.
The Brain Pulse Monitor enables early detection and treatment of brain hypoxia for unconscious and intubated patients in Intensive Care Units and the Operating Theatre.
We help clinicians:
minimise the likelihood of misjudging the risk of brain tissue injury.
minimise the time it takes to determine how the brain injury will impact the treatment being considered or provided.
minimise the risk of further brain injury and infection inherit in the current invasive monitoring standard of care.
reduce the cost of care in high value ICU and Operating Theatre settings.
Fusetec
Fusetec was founded in 2017, to answer the research question, ‘’How Do Surgeon’s Train.’’ Their mission is to improve healthcare outcomes by providing safe, affordable, and effective training alternatives to upskill residents and continually advance surgeon training.
The use of cadavers in surgical training is high risk, potentially infectious, highly regulated, costly and with limited access to pathology.
Fusetec is an IP centric company for the purposes of commercial activities they advance manufactures anatomically accurate, fully operable, surgical training models with pathology for surgical simulation training while disrupting the cadaver market and exports their products globally.
Fusetec’s journey is just beginning.
LBT Innovations
Profile coming soon.
OncoRes Medical
OncoRes Medical is on a mission is to revolutionise cancer surgery.
Complete surgical clearance is the foundation of curative cancer treatment for the 17 million patients globally diagnosed with a solid cancer each year. But, there are currently no accurate and easy to use technologies for surgeons to identify residual cancer remaining inside the patient during surgery, meaning a high proportion of patients will have cancer left behind.
OncoRes Medical is a clinical-stage company developing a category-defining digital imaging system for real-time cancer detection to guide precision surgical cancer clearance, starting with Breast Conserving Surgery. Our QME (Quantitative Micro-Elastography) Imaging system is designed by surgeons, for surgeons – a highly differentiated solution that fits seamlessly into surgical workflow, is simple to learn and use. It enables a new standard of care by providing information in real-time to surgeons about what remains inside the patient. QME is a novel, propriety technology that generates quantitative, 3D imaging data and measures micro-scale tissue stiffness.
Vaxxas
Vaxxas is a privately held, Australian-based biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious diseases and oncology.
To date, the company has had success in several clinical trials involving more than 500 participants including Phase I clinical studies for COVID-19, seasonal influenza and measles and rubella. In 2024, it will begin a Phase I study for pandemic influenza funded by the United States Government’s Biomedical Advanced Research and Development Authority (BARDA).
The company opened its global headquarters and first manufacturing facility in Brisbane in June 2023 with support from the Queensland government. From this site, Vaxxas is advancing toward first commercial products in the next three – five years.
Wellumio
Wellumio is a medical technology startup developing an ultra-portable MRI scanner (Axana) with a primary focus on early diagnostic triage for acute stroke, a leading cause of human mortality and disability. Co-founded in 2019 and led by co-CEOs Dr Shieak Tzeng and Dr Sergei Obruchkov, the company’s mission is to advance the availability and affordability of point-of-care imaging. Wellumio's second-generation scanner, Axana, achieves a 99% weight reduction compared to conventional MRI, establishing it as the most portable imaging system in the global USD15B mobile imaging services market.
AusBiotech is inviting investees and industry executives that are seeking to pitch and delegates to register for AusMedtechInvest 2024.
AusMedtechInvest 2024 is Australia’s inaugural boutique medtech investment roundtable forum and aims to build meaningful personal connections between innovative medical technology (devices and diagnostic) businesses and investors, and help great ideas attract the capital needed to thrive in a fast-paced, competitive market.
AusMedtechInvest is designed to create connections that will contribute to the advancement of the sector, foster growth, and drive investment and collaboration, in what continues to be a significant time for the medical research and medtech sector.
Pricing
All the prices below are inclusive of GST.
Investee pitching fee
Pitch for investment - Member
$2,500
Pitch for investment - Non-member
$3,950
Pitch for investment
Australian medical technology companies seeking to raise capital, whether listed or private, and span the spectrum of the medical technology industry are eligible to pitch for investment at AusMedtechInvest 2024. AusBiotech reserves the right to determine eligibility for presenting in this category.
Medical technology includes a wide range of medical devices (including in vitro diagnostics) used to diagnose, monitor or treat diseases in humans that are used within a hospital, general practitioner or home setting.
Become a member
Strengthen your connections in the Australian life sciences industry, benefit from longstanding relationships and help foster a sustainable and globally competitive sector. For more information please contact Tanya Daw, Director, Membership & Engagement, 0419 394 097.
AusPartnering
AusPartnering is AusBiotech’s highly popular business matching programme facilitating 1:1 meetings throughout the day. Pre-schedule thirty-minute meetings within the AusPartnering platform.
AusPartnering will be available for investees and investors only.
Paying delgates attending AusMedtechInvest will not have access into the partnering system.